Biopure Corporation
11 Hurley Street
Cambridge
Massachusetts
02141
United States
Tel: 617-234-6500
Fax: 617-234-6505
Website: http://www.biopure.com/
Email: biopure@biopure.com
About Biopure Corporation
Biopure gives new meaning to blood work. The company makes an artificial blood product based on bovine red blood cells to deliver oxygen to patients with acute blood loss, anemia, or who have had a stroke or a heart attack. Its Hemopure, for humans, and Oxyglobin, for dogs (already approved for veterinary use), are made of purified and processed cow blood, have a two-year shelf life, do not require blood typing, and release more oxygen than a blood transfusion. The blood products also are less viscous than red blood cells, allowing them to flow more easily through partially blocked or constricted blood vessels. Chairman and CEO Carl Rausch owns about 44% of the company.Last updated: 8-28-01
81 articles about Biopure Corporation
-
Biopure Corporation Auctions Assets to OPK Biotech for $4 Million
8/28/2009
-
Biopure Corporation Receives Notice of Delisting from Nasdaq
7/20/2009
-
Biopure Corporation Files Voluntary Petition for Relief Under Chapter 11 of the United States Bankruptcy Code
7/17/2009
-
Biopure Corporation Receives Notice of Nasdaq Delisting
6/30/2009
-
Biopure Corporation Release: U.S. Naval Medical Research Center Proposed 'RESUS' Clinical Trial in Trauma Patients Remains on FDA Hold
5/18/2009
-
Biopure Corporation Receives Notices About Nasdaq Listing Compliance
4/1/2009
-
Biopure Corporation Exploring Strategic Options
2/18/2009
-
Biopure Corporation Release: U.S. Navy Requested Operations Trial on FDA Hold
1/2/2009
-
Biopure Corporation Receives Extension of Time to Regain NASDAQ Listing Compliance
1/2/2009
-
Biopure Corporation Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia
12/17/2008
-
U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting
12/3/2008
-
Biopure Corporation Receives Extension of Time to Regain NASDAQ Listing Compliance
10/28/2008
-
Biopure Corporation Announces 2008 Third Quarter Financial Results
8/25/2008
-
Biopure Corporation Announces Meeting With FDA
7/7/2008
-
Biopure Corporation Phase III Orthopedic Trial Results Published in Journal of Trauma
6/11/2008
-
Biopure Corporation Announces MHRA Meeting Update
6/5/2008
-
Biopure Corporation Announces 2008 Second Quarter Financial Results
5/22/2008
-
Biopure Corporation Wins European Patent Challenge
5/19/2008
-
Biopure Corporation Announces Publication of Phase II Proof-of-Concept Coronary Trial
5/15/2008
-
Biopure Corporation Operations Compliant With U.K. Manufacturing Guidelines
4/11/2008